Valuation : Norda ASA

Market Cap 513M 55.32M 47.69M 45.11M 40.91M 76.21M 5.29B 77.13M 535M 206M 2.69B 208M 203M 8.44B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 28.5M 24.57M 23.24M 21.08M 39.26M 2.72B 39.73M 276M 106M 1.38B 107M 105M 4.35B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+0.12%
Current month+0.12%
1 month-1.50%
3 months-1.50%
Current year-14.90%
1 month 85
Extreme 85
85.1
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+0.12%0.00%+5.06%+107.56% 47.03M
-0.71%-6.35%-4.87%+9.03% 45.48B
+0.21%-2.98%+340.68%+519.93% 43.69B
+1.74%-2.24%+37.28%+21.57% 43.09B
+1.38%-3.28%+3.23%+65.60% 39.4B
-1.44%-5.26%+8.78%+36.85% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+18.07%+110.32% 16.4B
-0.31%-2.78%+10.47%+30.49% 14.24B
+1.93%-3.55%+74.20%+39.37% 13.28B
Average +0.45%-3.22%+54.77%+104.52% 26.48B
Weighted average by Cap. +0.41%-3.67%+73.15%+123.56%

Financials

2023 2024
Net sales 86.92M 9.37M 8.08M 7.64M 6.93M 12.91M 895M 13.06M 90.63M 34.91M 455M 35.19M 34.41M 1.43B 372M 40.09M 34.56M 32.69M 29.65M 55.22M 3.83B 55.89M 388M 149M 1.95B 151M 147M 6.12B
Net income 31.17M 3.36M 2.9M 2.74M 2.49M 4.63M 321M 4.69M 32.5M 12.52M 163M 12.62M 12.34M 513M 126M 13.58M 11.71M 11.07M 10.04M 18.7M 1.3B 18.93M 131M 50.58M 659M 50.99M 49.86M 2.07B
Net Debt -311M -33.55M -28.93M -27.36M -24.81M -46.22M -3.21B -46.78M -325M -125M -1.63B -126M -123M -5.12B -249M -26.82M -23.13M -21.87M -19.84M -36.95M -2.56B -37.4M -259M -99.93M -1.3B -101M -98.51M -4.09B
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. NORD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!